Summary & Overview
HCPCS J7635: Atropine Inhalation Solution, Compounded, Per mg
HCPCS Level II code J7635 denotes a compounded atropine inhalation solution in concentrated form, billed per milligram and supplied for use with durable medical equipment (DME). This code is relevant where inhaled anticholinergic therapy is compounded and dispensed for patients requiring nebulized delivery, and it affects billing, DME coordination, and pharmacy compounding workflows nationwide. National payers include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what J7635 represents clinically and operationally, how it intersects with DME-based inhalation services, and which payers are commonly involved in coverage decisions. The publication provides benchmarks and policy context for billing compounded inhalation medications, highlights common payer coverage patterns, and outlines practical billing elements such as unit-based reporting per milligram and the typical sites of service for administration. Data not available in the input is noted where applicable, including specific payer reimbursement rates, associated ICD-10 diagnoses, and related codes. This summary equips coding, pharmacy, and DME teams with a concise reference on J7635 for national billing and administrative planning.
Billing Code Overview
HCPCS Level II code J7635 represents atropine, inhalation solution, compounded product, supplied in a concentrated form and billed per milligram. This code applies to a compounded inhalation medication formulated with atropine for administration via durable medical equipment (DME) designed for inhalation therapy.
Service type: Compounded inhalation medication administration through DME
Typical site of service: Home or outpatient settings where DME inhalation devices are used, including patient residences and ambulatory infusion or respiratory therapy clinics.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with chronic obstructive pulmonary disease (COPD) and recurrent bronchospasm presents for inhaled bronchodilator therapy delivered via a durable medical equipment nebulizer. The prescriber orders a compounded concentrated form of inhaled atropine to be prepared by a pharmacy and supplied for administration through the patient’s home nebulizer. The clinical workflow includes a pulmonology or primary care evaluation documenting uncontrolled bronchospasm despite standard inhaled therapies, a written prescription specifying the compounded concentration and milligram dose, pharmacy compounding and labeling, coordination with durable medical equipment (DME) supplier for delivery of the inhalation device, and nursing or respiratory therapy education on nebulizer use and dosing. The patient receives the drug at home with follow‑up visits or telehealth assessments to monitor response and adverse effects such as dry mouth, tachycardia, or urinary retention. Documentation includes indication, dosage per milligram, route (inhalation), administration through DME, compounding details, and patient instruction records.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard service | Use when no special circumstances or modifiers apply to the billed compounded inhalation product. |